Icecure Medical Ltd ICCM

NAS: ICCM | ISIN: IL0011224156   15:48
1,040 USD (0,00%)
(0,00%)   15:48
Grafiek Icecure Medical Ltd Grafiek Icecure Medical Ltd

Icecure Medical Ltd in het nieuws

20 mei 2024 · IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase · Persbericht

7 mei 2024 · Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally · Persbericht

15 april 2024 · IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer · Persbericht

3 april 2024 · IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance · Persbericht

2 april 2024 · IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes · Persbericht

27 maart 2024 · IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 · Persbericht

19 maart 2024 · IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy · Persbericht

12 maart 2024 · IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes · Persbericht

7 maart 2024 · IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference · Persbericht

4 maart 2024 · IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 · Persbericht

Profiel Icecure Medical Ltd

Werknemers: 14

Aandelen Icecure Medical Ltd

Beurswaarde: 47,45 miljoen USD

Effecten: 45,62 miljoen

Beta: 0,60

Mijn selecties